Kenvue (KVUE) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Kenvue

NYSE•Consumer Defensive•Household & Personal Products

$19.31-0.25(-0.01%)Market closed

Market Cap

$37.09B

P/E

21.9x

P/S

2.4x

P/B

3.7x

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

How this company scores

ExcellentMetricSide Score: 80/100

Strongest: Profitability (25/25); weakest: Balance Sheet & Red Flags (14/25).

Profitability25/25

Growth16/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowStrong marginsHigh ROERising earnings

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 21.9x5y range 20.7x – 43.0x

Currently near its 12-quarter median.

P/S · 2.4x5y range 2.1x – 3.0x

Currently near its 12-quarter median.

P/B · 3.7x5y range 1.9x – 4.5x

Price & Volume

Market Cap $37.09B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $15.53B
Q. Revenue: $3.89B
TTM EBITDA: $3.28B
TTM Op. Income: $2.71B
Q. Op. Income: $706.00M
TTM Net Income: $1.69B
Q. Net Income: $430.00M
EPS: $0.22
Shares Out.: $1.92B

$15.53B in TTM revenue grew 3.5% YoY, reaching $3.89B last quarter. TTM EBITDA of $3.28B and TTM operating income of $2.71B show growth is flowing through to the bottom line. TTM net income of $1.69B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 4 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 59.5%
EBITDA Margin: 21.8%
Op. Margin: 18.2%
Net Margin: 11.1%

Op. margin of 18.2% is up 1.5% YoY — cost efficiency is improving. Net margin at 11.1% and gross margin of 59.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 9% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 21.9x
P/S Ratio: 2.4x
P/B Ratio: 3.7x

At 21.9x P/E, the stock trades within typical market levels. P/S of 2.4x and P/B of 3.7x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $26.67B
Cash: $1.04B
Long-Term Debt: $7.08B
Book Value: $10.16B
D/E Ratio: 0.7
Debt/EBITDA: 8.3

With $26.67B in assets and $7.08B in long-term debt, D/E is 0.7and book value is $10.16B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $700.00M
TTM Free Cash Flow: $2.34B
FCF Margin: 15.1%
FCF / Net Income: 1.4

TTM FCF of $2.34B on $700.00M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 7 consecutive quarters — an improving trend.